ESMO 2019 Kidney Cancer

Viewing 1-20 of 37 articles

ESMO 2019: Results from a Global Patient Survey: Diagnosis, Management, and Burden of Renal Cell Carcinomas - A Medical Oncologist’s Perspective

ESMO 2019: Results of the Phase 2 TRAXAR Study: A Randomized Phase 2 Trial of Axitinib and TRC105 (TRAX) versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma

ESMO 2019: Invited Discussant: (911PD and 912PD) New Anti-Angiogenic Treatments for Kidney Cancer

ESMO 2019: Patients with Advanced Renal Cell Carcinoma with Sarcomatoid Histology: A Subgroup Analysis on Efficacy and Biomarkers from the Phase 3 JAVELIN Renal 101 Trial of First-Line Avelumab plus Axitinib versus Sunitinib

ESMO 2019: A First-in-Human Phase 1/2 Trial of the Oral HIF-2a Inhibitor PT2977 in Patients with Advanced RCC - A Medical Oncologist's Perspective

ESMO 2019: ADAPTeR: Anti-PD1 Therapy as Operative Therapy in Metastatic Renal Cell Carcinoma

ESMO 2019: Phase 3 JAVELIN Renal 101 Trial of First-Line Avelumab + Axitinib vs. Sunitinib For Advanced Renal Cell Carcinoma

ESMO 2019: The Associated of CD8 Infiltration and PD-L1 Expression and Outcomes in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Nivolumab, NIVOREN GETUG-AFU 26 Translational Study

ESMO 2019: Phase 3 Trial of Adjuvant Sunitinib in Patients with High-risk Renal Cell Carcinoma: Comprehensive Tumor Genomic and Transcriptomic Analyses

ESMO 2019: Primary Renal Tumour Shrinkage in Patients who did not Undergo Upfront Cytoreductive Nephrectomy: Subgroup Analysis from Phase 3 JAVELIN Renal 101 Trial

ESMO 2019: Results of the Phase 2 TRAXAR Study: A Randomized Phase 2 Trial of Axitinib and TRC105 (TRAX) versus Axitinib Alone in Patients with Advanced or mRCC

ESMO 2019: Efficacy and Biomarker Analysis of Patients with Advanced Renal Cell Carcinoma with Sarcomatoid Histology: Subgroup Analysis from the Phase 3 JAVELIN Renal 101 Trial of First-line Avelumab Plus Axitinib vs Sunitinib

ESMO 2019: A First-in-Human Phase 1/2 Trial of the Oral HIF-2a Inhibitor PT2977 in Patients with Advanced RCC

ESMO 2019: Phase 3 Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Comprehensive Tumor Genomic and Transcriptomic Analyses

ESMO 2019: NIVOREN GETUG-AFU 26 Translational Study: CD8 Infiltration and PD-L1 Expression are Associated with Outcome in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Nivolumab

ESMO 2019: Diagnosis, Management, and Burden of Renal Cell Carcinomas: Results from a Global Patient Survey in 43 Countries

ESMO 2019: ADAPTeR - Phase II study of Anti-PD1 Therapy as Pre- and Post-Operative Therapy in Metastatic Renal Cell Carcinoma

ESMO 2019: Efficacy and Biomarker Analysis of Patients with Advanced Renal Cell Carcinoma with Sarcomatoid Histology: Subgroup Analysis from the Phase III JAVELIN Renal 101 Trial

ESMO 2019: Results of the Phase II TRAXAR Study: A Randomized Phase II Trial of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma

ESMO 2019: Invited Discussant: Germ Cell Tumor Studies and Renal Cell Carcinoma Disease Management Methods

1
2